Shares of Thyrocare Technologies surged more than 7% in early trade after the company posted a solid set of numbers for the June quarter of FY26, driven by double-digit growth in both revenue and profit. As of 9:40 AM, the shares were trading 7.26% higher at Rs 1,293.00.
Thyrocare’s consolidated revenue jumped 23% year-on-year (YoY) to ₹193.03 crore in Q1FY26, up from ₹156.91 crore in the same quarter last year. The strong topline growth was mainly led by its pathology business, which grew 25% YoY, while the radiology segment saw a moderate 6% uptick.
Within pathology, both business models performed well—franchise revenue rose 20% YoY, and the partnership model reported a sharp 36% YoY growth. The company also processed 46.9 million diagnostic tests during the quarter, reflecting a 15% increase over Q1FY25.
On the profitability front, Thyrocare reported normalized EBITDA (excluding ESOP costs) of ₹63.35 crore, up 42% YoY. Including all costs, EBITDA came in at ₹57.46 crore—marking a 37% increase. Net profit (PAT), including exceptional items, jumped 62% YoY to ₹38.06 crore.
In terms of expansion, Thyrocare added new labs in Bhagalpur, Kashmir, and Roorkee, bolstering its presence in Tier-2 and Tier-3 cities—an area of increasing focus for the company as it looks to scale its reach beyond metro markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
